Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review

Abstract Bosutinib, a BCR-ABL1 tyrosine kinase inhibitor (TKI), has been available for several years as a treatment for chronic-, accelerated-, and blast-phase chronic myeloid leukemia (CML), for patients with resistance or intolerance to prior therapy. In 2017, the BFORE trial demonstrated efficacy...

Full description

Bibliographic Details
Main Authors: Jorge E. Cortes, Jane F. Apperley, Daniel J. DeAngelo, Michael W. Deininger, Vamsi K. Kota, Philippe Rousselot, Carlo Gambacorti-Passerini
Format: Article
Language:English
Published: BMC 2018-12-01
Series:Journal of Hematology & Oncology
Subjects:
Tyrosine kinase inhibitor
Bosutinib
Chronic myeloid leukemia
Dosing strategies
Adverse events
Online Access:http://link.springer.com/article/10.1186/s13045-018-0685-2

Internet

http://link.springer.com/article/10.1186/s13045-018-0685-2

Similar Items